Literature DB >> 28184968

Regulation of PD-L1 expression on murine tumor-associated monocytes and macrophages by locally produced TNF-α.

Genevieve Hartley1, Daniel Regan1, Amanda Guth1, Steven Dow2.   

Abstract

PD-L1 is an immune checkpoint protein that has emerged as a major signaling molecule involved with tumor escape from T cell immune responses. Studies have shown that intra-tumoral expression of PD-L1 can inhibit antitumor immune responses. However, it has recently been shown that expression of PD-L1 on myeloid cells from the tumor is a stronger indicator of prognosis than tumor cell PD-L1 expression. Therefore, it is important to understand the factors that govern the regulation of PD-L1 expression on tumor-infiltrating myeloid cells. We found that immature bone marrow monocytes in tumor-bearing mice had low levels of PD-L1 expression, while higher levels of expression were observed on monocytes in circulation. In contrast, macrophages found in tumor tissues expressed much higher levels of PD-L1 than circulating monocytes, implying upregulation by the tumor microenvironment. We demonstrated that tumor-conditioned media strongly induced increased PD-L1 expression by bone marrow-derived monocytes and TNF-α to be a cytokine that causes an upregulation of PD-L1 expression by the monocytes. Furthermore, we found production of TNF-α by the monocytes themselves to be a TLR2-dependent response to versican secreted by tumor cells. Thus, PD-L1 expression by tumor macrophages appears to be regulated in a different manner than by tumor cells themselves.

Entities:  

Keywords:  Cytokine; Immune checkpoint; Myeloid; Tumor

Mesh:

Substances:

Year:  2017        PMID: 28184968      PMCID: PMC6469500          DOI: 10.1007/s00262-017-1955-5

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  33 in total

1.  Frameshift events predict anti-PD-1/L1 response in head and neck cancer.

Authors:  Glenn J Hanna; Patrick Lizotte; Megan Cavanaugh; Frank C Kuo; Priyanka Shivdasani; Alexander Frieden; Nicole G Chau; Jonathan D Schoenfeld; Jochen H Lorch; Ravindra Uppaluri; Laura E MacConaill; Robert I Haddad
Journal:  JCI Insight       Date:  2018-02-22

2.  PD-L1 Binds to B7-1 Only In Cis on the Same Cell Surface.

Authors:  Apoorvi Chaudhri; Yanping Xiao; Alyssa N Klee; Xiaoxu Wang; Baogong Zhu; Gordon J Freeman
Journal:  Cancer Immunol Res       Date:  2018-06-05       Impact factor: 11.151

3.  Diminished PD-L1 regulation along with dysregulated T lymphocyte subsets and chemokine in ANCA-associated vasculitis.

Authors:  Jagdeep Singh; Ranjana Walker Minz; Biman Saikia; Ritambhra Nada; Aman Sharma; Saket Jha; Shashi Anand; Manish Rathi; Sanjay D'Cruz
Journal:  Clin Exp Med       Date:  2022-10-11       Impact factor: 5.057

4.  The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents.

Authors:  Carlos Zamora Atenza; Geòrgia Anguera; Mariona Riudavets Melià; Letícia Alserawan De Lamo; Ivana Sullivan; Andrés Barba Joaquin; Jorgina Serra Lopez; M Angels Ortiz; Maria Mulet; Sílvia Vidal; Margarita Majem
Journal:  Cancer Immunol Immunother       Date:  2022-01-05       Impact factor: 6.630

Review 5.  The proprotein convertase furin in cancer: more than an oncogene.

Authors:  Abdel-Majid Khatib; John W M Creemers; Zongsheng He
Journal:  Oncogene       Date:  2022-01-07       Impact factor: 8.756

6.  Aberrant expression of miR-16, B12 and CD272 in peripheral blood mononuclear cells from patients with active tuberculosis.

Authors:  Dongzi Lin; Qiankun Liu; Wei Wang; Yanyun Li; Yumei Li; Bihua Lin; Ziyu Ye; Juan Huang; Xiaolin Yu; Yinwen Chen; Yuezhi Mei; Minyuan Huang; Weiqin Yang; Jie Zhou; Xinguang Liu; Jincheng Zeng
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

7.  CMTM6-Deficient Monocytes in ANCA-Associated Vasculitis Fail to Present the Immune Checkpoint PD-L1.

Authors:  Markus Zeisbrich; Nina Chevalier; Bettina Sehnert; Marta Rizzi; Nils Venhoff; Jens Thiel; Reinhard E Voll
Journal:  Front Immunol       Date:  2021-05-24       Impact factor: 7.561

Review 8.  Defects in Macrophage Reprogramming in Cancer Therapy: The Negative Impact of PD-L1/PD-1.

Authors:  Hao Cai; Yichi Zhang; Jian Wang; Jinyang Gu
Journal:  Front Immunol       Date:  2021-06-23       Impact factor: 7.561

9.  NSD1 inactivation defines an immune cold, DNA hypomethylated subtype in squamous cell carcinoma.

Authors:  Kevin Brennan; June Ho Shin; Joshua K Tay; Marcos Prunello; Andrew J Gentles; John B Sunwoo; Olivier Gevaert
Journal:  Sci Rep       Date:  2017-12-06       Impact factor: 4.379

10.  Tumor-promoting effects of pancreatic cancer cell exosomes on THP-1-derived macrophages.

Authors:  Samuel S Linton; Thomas Abraham; Jason Liao; Gary A Clawson; Peter J Butler; Todd Fox; Mark Kester; Gail L Matters
Journal:  PLoS One       Date:  2018-11-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.